2190 — Zylox-Tonbridge Medical Technology Co Cashflow Statement
0.000.00%
- HK$11.87bn
- HK$10.60bn
- CNY782.48m
Annual cashflow statement for Zylox-Tonbridge Medical Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | PROSPECTUS | ARS | ARS | ARS | |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | -100 | -200 | -114 | -78.7 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 22.4 | 55.9 | -5.84 | 16 | — |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -13.9 | 14.2 | 1.8 | 125 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -82.3 | -116 | -91.3 | 98.4 | — |
Capital Expenditures | -45.1 | -89.6 | -145 | -191 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -204 | -1,239 | 50.2 | -15.3 | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -249 | -1,328 | -95 | -206 | — |
Financing Cash Flow Items | 336 | 399 | -0.722 | -1.25 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 346 | 2,810 | -30.3 | -11.5 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 13.4 | 1,359 | -213 | -119 | — |